Google
MDT Stock Analysis — MEDTRONIC PLC (Healthcare >> Medical Devices)
MDT FAQ
What is MDT's P/E ratio?
MEDTRONIC PLC (MDT) currently trades at a P/E ratio of 22.91.
What is MDT's ROE?
MEDTRONIC PLC reports a Return on Equity (ROE) of 9.70%.
What is MDT's dividend yield?
MEDTRONIC PLC offers a dividend yield of 3.24%.
What is MDT's Quality Score?
Our AI rates MDT's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MDT?
Our AI Timing Score for MDT is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MDT belong to?
MEDTRONIC PLC is classified under the Healthcare >> Medical Devices sector on the NYSE exchange
MDT AI Analysis Summary
Our AI summary for MDT: MEDTRONIC PLC (NYSE), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 22.91, ROE of 9.70%, a dividend yield of 3.24%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 85.39
Price
-0.32
(-0.37%)
Day Change
|
|
|---|
MDT, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROE is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is ok , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
1638
|
| Magic Formula Rank by ROE |
1638
|
| Magic Formula Rank by ROIC |
1943
|
| Price | 85.39 |
| PBV / Sector |
2.20 / -101.57
|
| Earning Per Share | 3.73 |
| PE / Sector |
22.91 / 31.23
|
| PEG or PE/Growth / Sector |
1.59 / 0.40
|
| Average 1M Daily Value |
564.57 M
|
| Average 1W Daily Value |
693.63 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
52% |
| Ability to Make Profit |
|
62% |
| Return to Investors |
|
62% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:09 |
| Symbol | MDT |
| Name | MEDTRONIC PLC |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE |
| Listed Shares | 1,280.05 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 109,990.86 / 20,104.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building Two, Galway, Ireland, H91 4K49
Phone: 353 1 438 1700
Website: https://www.medtronic.com
Employees: 95,000
Sector: Healthcare >> Medical Devices
Description: Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
